Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma

/PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address...

Related Keywords

United States ,Barry Kappel ,Amy Conrad ,Gina Capiaux ,Regulatory Affairs ,European Commission ,Drug Administration ,Prnewswire Sapience Therapeutics Inc ,Sapience Therapeutics Inc ,Orphan Drug Designation ,Vice President ,Drug Designation ,Fast Track Designation ,Fast Track ,Sapience Therapeutics ,Chief Executive ,Investor Contact ,Nc ,